{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:32:00Z","timestamp":1775863920353,"version":"3.50.1"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Anti-cancer treatment regimens can lead to both acute- and long-term myocardial injury due to off-target effects. Besides, cancer patients and survivors are severely immunocompromised due to the harsh effect of anti-cancer therapy targeting the bone marrow cells. Cancer patients and survivors can therefore be potentially extremely clinically vulnerable and at risk from infectious diseases. The recent global outbreak of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its infection called coronavirus disease 2019 (COVID-19) has rapidly become a worldwide health emergency, and on March 11, 2020, COVID-19 was declared a global pandemic by the World Health Organization (WHO). A high fatality rate has been reported in COVID-19 patients suffering from underlying cardiovascular diseases. This highlights the critical and crucial aspect of monitoring cancer patients and survivors for potential cardiovascular complications during this unprecedented health crisis involving the progressive worldwide spread of COVID-19. COVID-19 is primarily a respiratory disease; however, COVID-19 has shown cardiac injury symptoms similar to the cardiotoxicity associated with anti-cancer therapy, including arrhythmia, myocardial injury and infarction, and heart failure. Due to the significant prevalence of micro- and macro-emboli and damaged vessels, clinicians worldwide have begun to consider whether COVID-19 may in fact be as much a vascular disease as a respiratory disease. However, the underlying mechanisms and pathways facilitating the COVID-19-induced cardiac injury in cancer and non-cancer patients remain unclear. Investigations into whether COVID-19 cardiac injury and anti-cancer drug-induced cardiac injury in cancer patients and survivors might synergistically increase the cardiovascular complications and comorbidity risk through a \u201ctwo-hit\u201d model are needed. Identification of cardiac injury mechanisms and pathways associated with COVID-19 development overlapping with anti-cancer therapy could help clinicians to allow a more optimized prognosis and treatment of cancer survivors suffering from COVID-19. The following review will focus on summarizing the harmful cardiovascular risk of COVID-19 in cancer patients and survivors treated with an anti-cancer drug. This review will improve the knowledge of COVID-19 impact in the field of cardio-oncology and potentially improve the outcome of patients.<\/jats:p>","DOI":"10.3389\/fcvm.2021.634291","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T04:53:16Z","timestamp":1619153596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19"],"prefix":"10.3389","volume":"8","author":[{"given":"Caroline","family":"Lozahic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Maddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardip","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"c3750","DOI":"10.1136\/bmj.c3750","article-title":"Long term cancer survival rates double in England and Wales in past 40 years","volume":"341","author":"O'Dowd","year":"2010","journal-title":"BMJ."},{"key":"B2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1042\/CS20120620","article-title":"Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury","volume":"126","author":"Sandhu","year":"2014","journal-title":"Clin Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Current Cardiol Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.2217\/fon.15.198","article-title":"Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?","volume":"11","author":"Rebe","year":"2015","journal-title":"Future Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/asheducation-2005.1.516","article-title":"Considerations for adult cancer survivors","volume":"2005","author":"Tichelli","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Prog."},{"key":"B7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.21873\/invivo.11155","article-title":"Influenza among breast cancer survivors in south korea: a nationwide population-based study","volume":"31","author":"Heo","year":"2017","journal-title":"In Vivo."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1164\/rccm.202003-0817LE","article-title":"COVID-19 does not lead to a \u201ctypical\u201d acute respiratory distress syndrome","volume":"201","author":"Gattinoni","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"B10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ajem.2020.04.048","article-title":"Cardiovascular complications in COVID-19","volume":"38","author":"Long","year":"2020","journal-title":"Am J Emerg Med."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202004.0128.v1","article-title":"Cardiovascular vulnerability to COVID-19 in cancer survivors","author":"Zordoky","year":"2020","journal-title":"Preprints."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0891-5849(97)00025-7","article-title":"Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity","volume":"23","author":"Gille","year":"1997","journal-title":"Free Radic Biol Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1006\/excr.2000.4838","article-title":"Induction of apoptosis by cancer chemotherapy","volume":"256","author":"Kaufmann","year":"2000","journal-title":"Exp Cell Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.87.11.4275","article-title":"Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro","volume":"87","author":"Ito","year":"1990","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.pharmthera.2009.10.002","article-title":"Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy","volume":"125","author":"Raschi","year":"2010","journal-title":"Pharmacol Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","article-title":"Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology","volume":"136","author":"Varricchi","year":"2017","journal-title":"Circulation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","article-title":"Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.3390\/cancers12113316","article-title":"SARS-CoV-2 infection and cardioncology: from cardiometabolic risk factors to outcomes in cancer patients","volume":"12","author":"Quagliariello","year":"2020","journal-title":"Cancers."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/cncr.2820360904","article-title":"High dose cyclophosphamide therapy in solid tumors: therapeutic, toxic, and immunosuppressive effects","volume":"36","author":"Mullins","year":"1975","journal-title":"Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor","volume":"68","author":"Goldberg","year":"1986","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/0002-8703(83)90651-8","article-title":"Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity","volume":"106","author":"McKillop","year":"1983","journal-title":"Am Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","article-title":"Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO clinical practice guidelines","volume":"21","author":"de Naurois","year":"2010","journal-title":"Ann Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.21873\/invivo.11860","article-title":"Incidence of influenza among childhood cancer survivors in South Korea: a population-based retrospective analysis","volume":"34","author":"Heo","year":"2020","journal-title":"In Vivo."},{"key":"B32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.amepre.2014.01.007","article-title":"Influenza vaccination coverage among adult survivors of pediatric cancer","volume":"46","author":"Ojha","year":"2014","journal-title":"Am J Prev Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J Autoimmun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jmv.25689","article-title":"Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China","volume":"92","author":"Wang","year":"2020","journal-title":"J Med Virol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1056\/NEJMc2001272","article-title":"Importation and human-to-human transmission of a novel coronavirus in Vietnam","volume":"382","author":"Phan","year":"2020","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1148\/radiol.2020200236","article-title":"CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia","volume":"295","author":"Lei","year":"2020","journal-title":"Radiology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s11357-020-00198-w","article-title":"COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches","volume":"42","author":"Moccia","year":"2020","journal-title":"Geroscience."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1111\/bph.15207","article-title":"Sex-related differences in COVID-19 lethality","volume":"177","author":"Penna","year":"2020","journal-title":"Br J Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10557-005-6900-8","article-title":"Rethinking the renin-angiotensin system and its role in cardiovascular regulation","volume":"19","author":"Pagliaro","year":"2005","journal-title":"Cardiovasc Drugs Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fmed.2020.00335","article-title":"ACE\/ACE2 ratio: a key also in 2019 coronavirus disease (Covid-19)?","volume":"7","author":"Pagliaro","year":"2020","journal-title":"Front Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamacardio.2020.1329","article-title":"The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science","volume":"5","author":"AlGhatrif","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2951-z","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature."},{"key":"B45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"12910","DOI":"10.1074\/jbc.REV120.013930","article-title":"The molecular virology of coronaviruses","volume":"295","author":"Hartenian","year":"2020","journal-title":"J Biol Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature."},{"key":"B49","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1172\/JCI60331","article-title":"The acute respiratory distress syndrome","volume":"122","author":"Matthay","year":"2012","journal-title":"J Clin Invest."},{"key":"B51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1046\/j.1440-1681.1999.03078.x","article-title":"Physiological genetics: application to hypertension research","volume":"26","author":"Jacob","year":"1999","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia","volume":"221","author":"Zhang","year":"2020","journal-title":"J Infect Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3906\/sag-2004-168","article-title":"COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs","volume":"50","author":"Tufan","year":"2020","journal-title":"Turk J Med Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"117723","DOI":"10.1016\/j.lfs.2020.117723","article-title":"Myocardial injury and COVID-19: possible mechanisms","volume":"253","author":"Babapoor-Farrokhran","year":"2020","journal-title":"Life Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","volume":"5","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/jamacardio.2020.1096","article-title":"Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Inciardi","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.abe2813","article-title":"COVID-19 can affect the heart","volume":"370","author":"Topol","year":"2020","journal-title":"Science."},{"key":"B64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/CIRCRESAHA.120.317447","article-title":"The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications","volume":"127","author":"McFadyen","year":"2020","journal-title":"Circ Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/eurheartj\/ehaa623","article-title":"COVID-19 is, in the end, an endothelial disease","volume":"41","author":"Libby","year":"2020","journal-title":"Eur Heart J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/cvr\/cvaa078","article-title":"The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2","volume":"116","author":"Chen","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China","volume":"5","author":"Shi","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/jmv.25809","article-title":"Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China","volume":"92","author":"Han","year":"2020","journal-title":"J Med Virol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/CIRCRESAHA.120.317055","article-title":"COVID-19 and the heart","volume":"126","author":"Akhmerov","year":"2020","journal-title":"Circ Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s15010-020-01424-5","article-title":"First case of COVID-19 complicated with fulminant myocarditis: a case report and insights","volume":"48","author":"Zeng","year":"2020","journal-title":"Infection."},{"key":"B74","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/eurheartj\/ehaa190","article-title":"Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin","volume":"42","author":"Hu","year":"2021","journal-title":"Eur Heart J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.hrthm.2020.05.001","article-title":"Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management","volume":"17","author":"Siripanthong","year":"2020","journal-title":"Heart Rhythm."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/CM9.0000000000000744","article-title":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province","volume":"133","author":"Liu","year":"2020","journal-title":"Chin Med J."},{"key":"B78","doi-asserted-by":"publisher","first-page":"E216","DOI":"10.1148\/radiol.2020201629","article-title":"Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the national institute for public health of the Netherlands","volume":"297","author":"Oudkerk","year":"2020","journal-title":"Radiology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"E189","DOI":"10.1148\/radiol.2020201561","article-title":"Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-dimer levels","volume":"296","author":"Leonard-Lorant","year":"2020","journal-title":"Radiology."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e936","DOI":"10.1634\/theoncologist.2020-0213","article-title":"A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group","volume":"25","author":"Al-Shamsi","year":"2020","journal-title":"Oncologist."},{"key":"B81","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","article-title":"The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors","volume":"15","author":"Tocchetti","year":"2013","journal-title":"Eur J Heart Fail."},{"key":"B86","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bcp.12387","article-title":"Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials","volume":"78","author":"Qi","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1182\/blood.V126.23.4257.4257","article-title":"Biomarkers of cardiotoxicity among multiple myeloma patients subsequently treated with proteasome inhibitor therapy","volume":"126","author":"Lendvai","year":"2015","journal-title":"Blood."},{"key":"B88","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fcvm.2020.00032","article-title":"The utility of cardiac reserve for the early detection of cancer treatment-related cardiac dysfunction: a comprehensive overview","volume":"7","author":"Foulkes","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11912-020-00990-z","article-title":"Cancer risk in the heart failure population: epidemiology, mechanisms, and clinical implications","volume":"23","author":"Cuomo","year":"2020","journal-title":"Curr Oncol Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood."},{"key":"B94","doi-asserted-by":"publisher","first-page":"e000933","DOI":"10.1136\/jitc-2020-000933","article-title":"COVID-19 and immune checkpoint inhibitors: initial considerations","volume":"8","author":"Sullivan","year":"2020","journal-title":"J Immunother Cancer."},{"key":"B95","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"ix-x:1","DOI":"10.3310\/hta11270","article-title":"Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review","volume":"11","author":"Bryant","year":"2007","journal-title":"Health Technol Assess."},{"key":"B98","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.jacc.2015.04.012","article-title":"Subclinical cardiotoxicity associated with cancer therapy: early detection and future directions","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/MPH.0b013e3182532078","article-title":"Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia","volume":"34","author":"Goldberg","year":"2012","journal-title":"J Pediatr Hematol Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ."},{"key":"B104","first-page":"553","article-title":"Serum levels of cytokines in patients with untreated primary lung cancer","volume":"2","author":"Katsumata","year":"1996","journal-title":"Clin Cancer Res."},{"key":"B105","first-page":"3317","article-title":"Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma","volume":"52","author":"Blay","year":"1992","journal-title":"Cancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/0002-9378(91)90582-C","article-title":"Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer","volume":"164","author":"Berek","year":"1991","journal-title":"Am J Obstet Gynecol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/cancers12082237","article-title":"Cancer management during COVID-19 pandemic: is immune checkpoint inhibitors-based immunotherapy harmful or beneficial?","volume":"12","author":"Vivarelli","year":"2020","journal-title":"Cancers."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.634291\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T04:53:23Z","timestamp":1619153603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.634291\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":107,"alternative-id":["10.3389\/fcvm.2021.634291"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.634291","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"article-number":"634291"}}